Friday, September 13th, 2019
7:00 am - 8:25 am Welcome Desk Registration and Opening remarks
8:25 am - 8:30 am OPENING INTRODUCTION

8:30 am - 10:00 am BREAST CANCER
Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx.

Breast Cancer - 503

Presented by: Dr. Nuhad Ibrahim
SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) chemotherapy (C) versus trastuzumab (T) C in patients (pts) with HER2 metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).

Breast Cancer 1000

Presented by: Dr. Nuhad Ibrahim
Neratinib capecitabine versus lapatinib capecitabine in patients with HER2 metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.

Breast Cancer - 1002

Presented by: Dr. Nuhad Ibrahim
IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).

Breast Cancer - 1003

Presented by: Dr. Nuhad Ibrahim
Phase III MONALEESA-7 trial of premenopausal patients with HR /HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results.

Breast Cancer - LBA1008

Presented by: Dr. Faisal Al Terkait
Alpelisib (ALP) with fulvestrant (FUL) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Primary or secondary resistance to prior endocrine therapy (ET) in the SOLAR-1 trial.

Breast Cancer - 1038

Presented by: Dr. Anwar Al Nouri
Patient-reported outcomes (PROs) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) from SOLAR-1.

Breast Cancer - 1039

Presented by: Dr. Anwar Al Nouri
Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results.

Breast Cancer - 1040

Presented by: Dr. Emad Dawoud
QUESTIONS & ANSWERS

10:00 am - 10:30 am OPENING CEREMONY & EXHIBITION TOUR
10:30 am - 10:45 am COFFEE BREAK
10:45 am - 11:15 am Symposium by Amgen

11:15 am - 11:45 am GYNECOLOGIC CANCER
A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG oncology trial.

Gynecologic Cancer - 5500

Presented by: Dr. Hassan Jaafar
Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer. A randomized controlled chemotherapy-free study—NSGO-AVANOVA2/ENGOT-OV24.

Gynecologic Cancer - 5505

Presented by: Dr. Hassan Jaafar
QUESTIONS & ANSWERS

11:45 am - 12:15 pm MELANOMA/SKIN CANCERS
Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial.

Melanoma/Skin Cancers, Sarcoma, Symptoms and Survivorship - 2512

Presented by: Dr. Dima Abduljabbar
Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).

Melanoma/Skin Cancers, Sarcoma, Symptoms and Survivorship - 9501

Presented by: Dr. Dima Abduljabbar
QUESTIONS & ANSWERS
12:15 pm - 2:00 pm PRAYER AND LUNCH BREAK
2:00 pm - 3:00 pm Satellite Symposium by Pfizer - by invitation only

2:00 pm - 3:00 pm SYMPTOMS AND SURVIVORSHIP
The impact of routine ESAS use on overall survival: Results of a population-based retrospective matched cohort analysis.

Symptoms and Survivorship - 6509

Presented by: Dr. Maroun El Khoury
Effects of exercise on cancer-related fatigue and muscular strength in patients with breast cancer.

Symptoms and Survivorship - 11507

Presented by: Dr. Maroun El Khoury
Safety of pregnancy following breast cancer (BC) in patients (pts) carrying a BRCA mutation (mBRCA): Results of an international cohort study.

Symptoms and Survivorship - 11506

Presented by: Dr. Aydah Al-Awadhi
A randomized controlled trial of a novel artificial intelligence-based smartphone application to optimize the management of cancer-related pain.

Symptoms and Survivorship - 11514

Presented by: Dr. Aydah Al-Awadhi
A randomized, double-blind, placebo-controlled phase III trial evaluating olanzapine 5 mg combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: J-FORCE Study.

Symptoms and Survivorship - 11503

Presented by: Dr. Aydah Al-Awadhi
QUESTIONS & ANSWERS

3:00 pm - 4:15 pm LUNG CANCER
Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).

Lung Cancer - 8503

Presented by: Dr. Fathi Azribi
Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study.

Lung Cancer - 8504

Presented by: Dr. Fathi Azribi
Efficacy and safety profile of Lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial

Lung Cancer - 8506

Presented by: Dr. Fathi Azribi
RELAY: A multicenter, double-blind, randomized Phase 3 study of erlotinib in combination with ramucirumab or placebo in previously untreated patients with epidermal growth factor receptor mutation-positive metastatic non-small cell lung cancer.

Lung Cancer - 9000

Gefitinib versus gefitinib-pemetrexed-carboplatin in EGFR mutated lung cancer (Gef vs. Gef + C).

Lung Cancer - 9001

ECOG-ACRIN 5508: Pemetrexed, bevacizumab or the combination as maintenance therapy for advanced non-squamous non-small cell lung cancer.

Lung Cancer - 9002

QUESTIONS & ANSWERS
4:15 pm - 4:30 pm COFFEE BREAK

4:30 pm - 5:30 pm HEAD AND NECK
Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Head and Neck - 6000

Presented by: Dr. Diaeddine Trad
TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Head and Neck - 6002

Presented by: Dr. Diaeddine Trad
Gemcitabine and cisplatin (GP) induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) versus CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC): A phase 3, multicenter, randomized controlled trial.

Head and Neck - 6003

Presented by: Dr. Aref Chehal
Primary analysis of Phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (laCSCC).

Head & Neck - 6015

Presented by: Dr. Aref Chehal
QUESTIONS & ANSWERS
5:30 pm - 6:10 pm Symposium by Bristol-Myers Squibb
Saturday, September 14th, 2019
7:30 am - 8:30 am Welcome Desk Registration

8:30 am - 9:00 am GASTROINTESTINAL NON COLORECTAL CANCER
Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.

Gastrointestinal Cancer - LBA 4 - Plenary Session

Presented by: Dr. Robert Wolff
APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.

Gastrointestinal Cancer - 4000

Presented by: Dr. Robert Wolff
ABC-06 | A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.

Gastrointestinal Cancer - 4003

Presented by: Dr. Robert Wolff
9:00 am - 9:30 am Symposium by Servier

9:30 am - 10:00 am GASTROINTESTINAL COLORECTAL CANCER
Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).

Gastrointestinal Cancer - 3501

Presented by: Dr. Jasem Al Barrak
FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer.

Gastrointestinal Cancer - 3504

Presented by: Dr. Jasem Al Barrak
Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC.

Gastrointestinal Cancer - 3508

Presented by: Dr. Jasem Al Barrak
QUESTIONS & ANSWERS
10:00 am - 10:30 am Symposium by Pfizer Biosimilar
10:30 am - 10:45 am COFFEE BREAK

10:45 am - 12:15 pm GENITOURINARY: PROSTATE AND NON-PROSTATE CANCER
Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.

Genitourinary: Prostate and Non-Prostate Cancer - LBA 2 - Plenary Session

First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

Genitourinary: Prostate and Non-Prostate Cancer - 5006

Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).

Genitourinary Cancer - 5008

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.

Genitourinary Cancer - 4500

Presented by: Dr. Jawaher Ansari
EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors.

Genitourinary Cancer - LBA4505

Presented by: Dr. Jawaher Ansari
Consistent efficacy of nivolumab plus ipilumab across number of IMDC risk factors.

Genitourinary Cancer - 4574

Presented by: Dr. Emad Dawoud
Posthoc analyses of nivolumab plus ipilumab or sunitinib in IMDC inter/poor risk previously untreated aRCC with sarcomatoid features.

Genitourinary Cancer - 4513

Presented by: Dr. Emad Dawoud
Safety and efficacy of nivolumab plus ipilumab in patients with a RCC with brain metastases.

Genitourinary Cancer - 4517

Presented by: Dr. Emad Dawoud
QUESTIONS & ANSWERS
12:15 pm - 12:45 pm Symposium by Bristol-Myers Squibb
12:45 pm - 1:45 pm LUNCH BREAK

1:45 pm - 2:45 pm CENTRAL NERVOUS SYSTEM
Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion.

Central Nervous System - 2000

Randomized phase IIb clinical trial of continuation or non-continuation with six cycles of temozolomide after the first six cycles of standard first-line treatment in patients with glioblastoma: A Spanish research group in neuro-oncology (GEINO) trial.

Central Nervous System - 2001

Updated predictive analysis of the WHO-defined molecular subgroups of low-grade gliomas within the high-risk treatment arms of NRG Oncology/RTOG 9802.

Central nervous System - 2002

Presented by: Dr. Basel Al Haj Ali
Single agent ONC201 in adult recurrent H3 K27M-mutant glioma.

Central Nervous System - 3005

Presented by: Dr. Aladdin Maarraoui
QUESTIONS & ANSWERS
2:45 pm - 3:00 pm COFFEE BREAK

3:00 pm - 4:15 pm HEMATOLOGIC MALIGNANCY
Effect of gilteritinib on survival in patients with FLT3-mutated (FLT3mut ) relapsed/refractory (R/R) AML who have common AML co-mutations or a high FLT3-ITD allelic ratio.

Hematologic Malignancy - 7000

Presented by: Dr. Asma Al Olama
Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRD–) in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) and comorb

Hematologic Malignancy - 7502

Presented by: Dr. Asma Al Olama
Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: Results from a randomized HOVON-Nordic Lymphoma Group phase III study.

Hematologic Malignancy - 7507

Presented by: Dr. Faraz Khan
E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.

Hematologic Malignancy - 8001

Presented by: Dr. Faraz Khan
A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).

Hematologic Malignancy - 8004

Presented by: Dr. Mahmoud Marashi
Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA.

Hematologic Malignancy - 8005

Presented by: Dr. Mahmoud Marashi
QUESTIONS & ANSWERS
4:15 pm - 4:45 pm Closing Remarks

Licensed by ASCO®

The American
Society of Clinical Oncology

In Partnership with

In Partnership with

In Collaboration with

In Collaboration with

Supported By

Supported By

Destination Partner

Destination Partner
...